Form 4: Chimerix Director Middleton Reports Disposal of Shares and Options Following Merger with Jazz Pharmaceuticals

Director Fred A. Middleton reports the disposal of Chimerix shares and options due to the merger with Jazz Pharmaceuticals, where shares were acquired for $8.55 each.

Summary

• Fred A. Middleton, a director of Chimerix, filed a Form 4 to report changes in beneficial ownership of Chimerix securities.
• The filing is related to the merger between Chimerix and Jazz Pharmaceuticals, which became effective on April 21, 2025.
• As a result of the merger, Middleton disposed of 2,776,093 shares of common stock held indirectly through Sanderling Venture Partners V, L.P. at a price of $8.55.
• He also disposed of 531,861 shares held indirectly through Sanderling Venture Partners VI Co-Investment Fund, L.P. at a price of $8.55.
• Additionally, Middleton disposed of 207,523 shares held directly at a price of $8.55.
• Middleton also disposed of various employee stock options as they were cancelled and converted into the right to receive a cash payment.
• The offer price for each share was $8.55 in cash.
• The merger was completed after the expiration of the tender offer on April 17, 2025.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as the document reports the completion of a merger, which typically provides shareholders with a defined cash value for their shares. The disposal of shares and options is a procedural outcome of the merger.

Future Outlook

The document does not contain specific forward-looking statements beyond the completion of the merger.

Management Comments

• The foregoing descriptions in the footnotes to this Form 4 are qualified in their entirety by reference to the terms of the Merger Agreement.
• In the event of any conflict between the descriptions above and the terms set forth in the Merger Agreement, the terms set forth in the Merger Agreement shall control.

Industry Context

This announcement reflects a merger and acquisition activity in the pharmaceutical industry, where companies like Jazz Pharmaceuticals acquire smaller entities like Chimerix to expand their portfolios or gain access to specific technologies or products.

Comparison to Industry Standards

• Mergers and acquisitions are common in the pharmaceutical industry, with deal sizes varying greatly depending on the target company's assets and pipeline.
• Comparable transactions would include acquisitions of biotech companies with promising drug candidates or established market presence.
• The $8.55 per share offer price reflects the valuation determined during the negotiation of the merger agreement, which may be influenced by factors such as market conditions, financial performance, and future growth prospects.

Stakeholder Impact

• Shareholders received $8.55 per share as a result of the merger.
• Employees may experience changes as Chimerix becomes a subsidiary of Jazz Pharmaceuticals.
• The merger could impact the availability and development of Chimerix's products under Jazz Pharmaceuticals' ownership.

Key Dates

Keywords

Chimerix, Jazz Pharmaceuticals, Merger, Form 4, Beneficial Ownership, Middleton, Shares, Options, Disposal, Tender Offer